Diabetes care products boost Novo Nordisk's sales in 1996
This article was originally published in Clinica
Executive Summary
Danish company Novo Nordisk's healthcare business recorded sales of DKr 11,078 million ($1,696 million), up 12%, in 1996. The healthcare and enzyme company reported 15% sales growth for its diabetes products, to DKr 7,784 million. This growth is due to increased sales of its Penfill for NovoPen injectors and the disposable NovoLet delivery system. Sales in the US and Asia, particularly Japan, were good. Group turnover was up 8% to DKr 14,873 million, and net income rose 15% to DKr 1,799 million.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.